Source comparison
PT-141 Alternatives 2026 Best: Research Compound Comparison
| Compound | Primary Mechanism | Receptor Target | Half-Life | Administration Route | Key Differentiator | Professional Assessment ||—|—|—|—|—|—|| MT-II (Melanotan II) | Melanocortin agonist | MC1R–MC5R (non-selective) | 33 hours | Subcutaneous | Broader recep
This comparison does not assign a generated winner or score.
- | Compound | Primary Mechanism | Receptor Target | Half-Life | Administration Route | Key Differentiator | Professional Assessment ||—|—|—|—|—|—|| MT-II (Melanotan II) | Melanocortin agonist | MC1R–MC5R (non-selective) | 33 hours | Subcutaneous | Broader receptor activity, produces tanning at therapeutic doses | Best for studies requiring sustained melanocortin signaling; incompatible with protocols requiring MC4R selectivity || PT-141 (Bremelanotide) | Melanocortin agonist | MC3R/MC4R (selective) | 2.7 hours | Subcutaneous, intranasal | Selective MC4R activity without MC1R-mediated tanning | Gold standard for on-demand arousal research; short half-life limits chronic dosing studies || Cabergoline | Dopamine agonist | D2 receptor | 63–69 hours | Oral | Lowers prolactin, indirect libido enhancement | Effective only in hyperprolactinemic models; no direct CNS arousal pathway || Kisspeptin-10 | GnRH stimulator | KISS1R (GPR54) | 30 minutes | Subcutaneous, IV | Activates reproductive axis